These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 17370399)
1. [Advantages of different dosages of active metabolites in the follow-up of azathioprine treatment for Crohn disease]. Cagnard B; Tosoni-Verlingue D; Tribut O; Moizard C; Bridoux-Henno L; Delaperriere N; Bentue-Ferrer D; Dabadie A Arch Pediatr; 2006 Oct; 13 Suppl 1():S67-8. PubMed ID: 17370399 [No Abstract] [Full Text] [Related]
2. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143 [TBL] [Abstract][Full Text] [Related]
3. [Is there any interest to dose the azathioprine's metabolites during inflammatory bowel diseases?]. Melaouhia S; Fékih M; Ferchichi H; Bouissorra H; Ben Mustapha N; Boubaker J; Filali A; Lakhal M; Klouz A Therapie; 2013; 68(5):313-20. PubMed ID: 24225042 [TBL] [Abstract][Full Text] [Related]
4. Azathioprine metabolite measurements: its use in current clinical practice. Rumbo C Pediatr Transplant; 2004 Dec; 8(6):606-8. PubMed ID: 15598334 [TBL] [Abstract][Full Text] [Related]
5. [Prevention of Crohn disease recurrence with azathioprine--for whom, how long?]. Koop I; Schreiber S Z Gastroenterol; 1997 Jan; 35(1):47-8. PubMed ID: 9123958 [No Abstract] [Full Text] [Related]
6. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961 [TBL] [Abstract][Full Text] [Related]
7. Predicting the need for azathioprine at first presentation in children with inflammatory bowel disease. Mossop H; Davies P; Murphy MS J Pediatr Gastroenterol Nutr; 2008 Aug; 47(2):123-9. PubMed ID: 18664861 [TBL] [Abstract][Full Text] [Related]
8. [Combined surgical and clinical therapy of regional enteritis]. Grewe HE; Lampe K; Berndt V Zentralbl Chir; 1971 Oct; 96(42):1448-59. PubMed ID: 5144187 [No Abstract] [Full Text] [Related]
9. A study of the utility of azathioprine metabolite testing in myasthenia gravis. Rae W; Burke G; Pinto A J Neuroimmunol; 2016 Apr; 293():82-85. PubMed ID: 27049566 [TBL] [Abstract][Full Text] [Related]
11. [Response to stopping azathioprine in Crohn's patients on combined treatment with infliximab]. Martín De Carpi J; Varea V An Pediatr (Barc); 2009 Mar; 70(3):271-7. PubMed ID: 19409244 [TBL] [Abstract][Full Text] [Related]
12. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease. Kwan LY; Devlin SM; Mirocha JM; Papadakis KA Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898 [TBL] [Abstract][Full Text] [Related]
13. Inflammatory bowel disease in the clinic: Escalation and de-escalation of therapy: A longitudinal case-based discussion. Begun J J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():12-3. PubMed ID: 26990807 [No Abstract] [Full Text] [Related]
14. [Azathioprine in Crohn disease]. Hoffmann R Dtsch Med Wochenschr; 1993 Apr; 118(13):480. PubMed ID: 8467748 [No Abstract] [Full Text] [Related]
15. Optimizing thiopurine therapy: more weight to the metabolite argument. Gibson PR; Gearry RB J Gastroenterol Hepatol; 2010 Oct; 25(10):1592-4. PubMed ID: 20880165 [No Abstract] [Full Text] [Related]
16. Azathioprine therapy in steroid-dependent patients with Crohn disease: results of a 10-year longitudinal follow-up study. Pinto AL; Chebli LA; Ribeiro MS; Pace FH; Moraes JP; do Amaral FJ; Gaburri PD; Meirelles de Souza AF; Chebli JM Med Sci Monit; 2009 May; 15(5):PI19-26. PubMed ID: 19396048 [TBL] [Abstract][Full Text] [Related]